Über uns
Über uns
Führungsteam
Partnerschaften
Technologie
Technologie
Produktion
Publikationen
Pipeline
Newsroom
News
Events
Downloads
Investor Relations
Überblick
Aktieninformation
Analysten-Coverage
Hauptversammlung 2022
Finanzberichte
Corporate Governance
E-Mail Alert
Karriere
Werden Sie Teil der RNA people
Ausbildung
Aktuelle Stellenangebote
DE
Oncology
The regulatory landscape for actively personalized cancer immunotherapies
by Sovereign
Developing mRNA-vaccine technologies
by Sovereign
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
by Sovereign
mRNA: delivering an antitumor message
by Sovereign
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
by Sovereign
Intradermal Vaccinations With RNA Coding for TAA Generate CD8(+) and CD4(+) Immune Responses and Induce Clinical Benefit in Vaccinated Patients
by Sovereign
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
by Sovereign
Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA
by Sovereign
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas
by Sovereign
1
2
